Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
Resistance to endocrine treatment in ER+/HER2- breast cancer patients remains a significant clinical problem. Here, the authors demonstrate that loss of the MutL mismatch repair complex can serve as a first-in-class predictive biomarker for combinatorial inhibition of HER2 to overcome the emergence...
Saved in:
Main Authors: | Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/65ef3b7f9a184674b715885b4857dafc |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015) -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
by: Fara Brasó-Maristany, et al.
Published: (2020) -
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
by: Avisek Majumder, et al.
Published: (2021) -
Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
by: Stenehjem DD, et al.
Published: (2014) -
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
by: Demet Candas-Green, et al.
Published: (2020)